Recognizing a need to further explore genomic profiling
in pediatric malignancies, the Hugs for Brady Foundation has committed $ 300,000 to the precision medicine initiative at Rutgers Cancer Institute of New Jersey.
The company's lead product candidate, dilanubicel (NLA101), is currently being evaluated
in two ongoing Phase 2 clinical trials
in adult and
pediatric patients with hematologic
malignancies undergoing an allogeneic transplant and adult patients receiving high dose chemotherapy for Acute Myeloid Leukemia.
Low - Dose ATLG Prevents GVHD
in Pediatric Hematologic
Malignancies: A newly published randomized phase III study of pediatric patients showed lower doses of rabbit anti — T - lymphocyte globulin (ATLG) was superior to a higher dose in children with hematologic malignancies undergoing allogeneic hematopoietic stem cell transplantation from an unre
Malignancies: A newly published randomized phase III study of
pediatric patients showed lower doses of rabbit anti — T - lymphocyte globulin (ATLG) was superior to a higher dose
in children with hematologic
malignancies undergoing allogeneic hematopoietic stem cell transplantation from an unre
malignancies undergoing allogeneic hematopoietic stem cell transplantation from an unrelated donor.